Partner

Kate Darracott

Languages

English

Social media

Kate Darracott is a partner in the Corporate Department. She specialises in international and domestic capital markets transactions (e.g. international public offerings, equity, debt and convertible follow-on offerings and private placements), strategic investments and acquisition financing. She also advises corporate clients on securities law compliance and disclosure questions as well as corporate governance matters.

As an attorney qualified in New York State, Kate has advised on a broad range of complex international transactions. Her clients range from fortune 500 companies to start-ups across a variety of sectors, including energy, finance, pharmaceuticals and biotech, technology, retail and e-commerce, amongst others.

Relevant experience

A variety of UK private limited companies and European companies in connection with potential initial public offerings and admissions to trading on the main market of the London Stock Exchange
NatWest Markets Plc on the establishment of its $10 billion medium-term notes program, admitted to trading on the Main Market of the London Stock Exchange
Centogene AG on its €51 million SEC-registered initial public offering and listing on NASDAQ
The underwriters in connection with Cellectis S.A.’s $164 million SEC-registered stock offering and listing on NASDAQ
The underwriters in connection with Deutsche Bank AG’s €8.6 billion rights offering on the Frankfurt and New York Stock Exchanges and for the establishment of Deutsche Bank AG’s MREL compliant $2.3 billion senior debt program
The underwriters in connection with First Data Corporation’s $2.5 billion SEC-registered initial public offering and stock exchange listing on NASDAQ, the largest IPO in the world that year
Visa Inc. in connection with an SEC-registered $16 billion debt financing for the acquisition of Visa Europe, as well as advice on various compliance, disclosure and corporate governance matters
The underwriters in connection with the SEC-registered offering of $570 million of common stock of General Motors Company, sold by the U.S. Department of the Treasury
AstraZeneca Plc in connection with their $2.9 billion, $2.9 billion, and $5 billion debt issuances and ongoing disclosure, reporting and compliance matters
A leading U.S. private property fund on various securities transactions in connection with financing their portfolio

Memberships & Roles

Steering committee member, American Lawyers in London
Member, American Bar Association
St. Andrews Society for the State of New York Scholar
Dr. John MacCormick Scholar

Education

2013 – Admitted to the New York Bar
2012 – LL.M, Harvard University
2010 – LL.B, Glasgow University

Practice Areas

Corporate Equity Capital Markets

sectors

Biotech

Insights by Kate

See all Insights

Legal Update United Kingdom

New deadlines approach for beneficial ownership reporting requirements in the US

09 Apr 2025 7 min read

Legal Update United Kingdom

Changes to the UK Listing Rules: Focus on the Controlling Shareholder Regime

05 Aug 2024 7 min read

Legal Update United Kingdom

Further transparency rules come into force: The US Corporate Transparency Act will require action by overseas companies

09 Jan 2024 8 min read

Publication United Kingdom

Addition by subtraction

11 Dec 2023 5 min read

Select your region

Kate Darracott

Languages

Social media

Relevant experience

Memberships & Roles

Education

Practice Areas

sectors

Insights by Kate

New deadlines approach for beneficial ownership reporting requirements in the US

Changes to the UK Listing Rules: Focus on the Controlling Shareholder Regime

Further transparency rules come into force: The US Corporate Transparency Act will require action by overseas companies

Addition by subtraction